Heart Failure March 9, 2026
Barostim Boosts QoL and LVEF, but Mortality Benefit Still Unknown March 9, 2026
Strong results from two separate studies on CVRx’s Barostim baroreflex activation therapy suggest the technology might offer symptomatic relief even though its mortality benefit is still up in the air. The first of two Barostim studies discussed at THT 2026, the REBALANCE registry enrolled 435 patients with a low average baseline LVEF, mostly NYHA class […]
Cardiology Testing March 5, 2026
What NT-proBNP Can Tell Us About TEER Outcomes March 5, 2026
New research presented at THT 2026 suggests that the NT-proBNP biomarker could give us a glimpse into which patients with severe tricuspid regurgitation (TR) will benefit the most from transcatheter edge-to-edge repair (TEER). Using data from the EuroTR registry, researchers evaluated 2.2k patients undergoing TEER, and organized them into three NT-proBNP categories (≤1,674, 1,675-3,743, >3,743 […]
Cardiology Testing March 2, 2026
Two Cardiac Troponins Don’t Tell the Same Story March 2, 2026
There might be a bigger difference between the types of cardiac troponin assays, after a recent JACC analysis found that the type of troponin could help us better understand the kind of damage occurring after a heart attack. As part of a multicohort validation, researchers examined 9.7k patients who were marked as having no known, […]
Cardiovascular Disease February 26, 2026
Women’s CVD Will Keep Rising by 2050 February 26, 2026
Imagine an America where two out of three women suffer from cardiovascular disease. What would it look like for your mother, sister, or daughter? The American Heart Association says you won’t have to imagine for long, with its latest scientific statement painting a grim picture of women’s cardiovascular health by 2050. Over the next 25 […]
Surgeries & Interventions February 23, 2026
Market Competition Drives TAVR Overutilization February 23, 2026
Whether or not a patient receives TAVR over SAVR might be more influenced by market forces than clinical evidence, after a recent study found that the more competitive the hospital market, the higher the TAVR likelihood, regardless of guideline recommendations. Examining 137k patients undergoing aortic valve replacement across seven states, researchers calculated hospital market competition […]
Heart Failure February 19, 2026
Rethinking Hyperkalemia Care in Patients With Heart Failure February 19, 2026
By Ravi Dhingra, MD, MPH, FACC, FAHASponsored By AstraZeneca Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is a cornerstone of heart failure (HF) management, yet concerns about hyperkalemia (HK) can limit its use.1 In chronic HF management, a long-term approach to addressing HK is an important consideration for healthcare providers. An observational study2 utilizing Optum’s de-identified Market Clarity Data […]
Surgeries & Interventions February 19, 2026
Evolut Low Risk, A Tale of Two Outcomes February 19, 2026
We might need to reconsider the concept of a TAVR-first strategy for low-risk aortic stenosis patients, after extended results from the Evolut Low Risk trial showed that reintervention rates at seven years were considerably higher in TAVR recipients compared to surgical replacement. As has been the case for each yearly follow-up, the trial examined 1.4k […]
Cardiology Pharmaceuticals February 16, 2026
DAPT Drugs Matter to Diabetics with Multivessel CAD February 16, 2026
The debate over which dual antiplatelet therapy is best for diabetic CAD patients might favor generic prasugrel over ticagrelor (AstraZeneca’s Brilinta), after the TUXEDO-2 trial demonstrated that ticagrelor isn’t equivalent to prasugrel in this complex patient group. The TUXEDO-2 trial enrolled 1.8k participants across 66 clinical sites in India and randomized patients undergoing PCI to […]
Artificial Intelligence February 12, 2026
Google’s AMIE Shows Promise for Cardiology Care February 12, 2026
AI scribes and LLMs’ potential impact on cardiology just became a lot clearer after a Stanford RCT published in Nature Medicine demonstrated that Google’s AMIE system helped general cardiologists better diagnose and plan treatment for rare heart conditions. Researchers enrolled nine general cardiologists to evaluate 107 patients with suspected genetic cardiovascular disease. Each case was […]
Cardiology Pharmaceuticals February 9, 2026
Statin Side Effects Might Not be So Bad February 9, 2026
New research in The Lancet suggests that statin underutilization might stem from unfounded safety fears rather than actual risk, after researchers found that 62 out of 66 the drugs’ package-listed adverse effects lack reliable evidence. In an attempt to clear statins’ name, researchers analyzed data from 19 large RCTs to distinguish real statin-associated risks from […]
Cardiology Business February 5, 2026
Medtronic Acquires CathWorks, Expands Cath Lab Presence February 5, 2026
Using AI algorithms to diagnose and assess coronary artery disease for intervention is about to become more mainstream after medtech giant, Medtronic, agreed to exercise its acquisition rights on AI FFR specialist, CathWorks, for $585M up-front. Until now CathWorks’ FFRangio has only been available in the U.S., Europe, and Japan through Medtronic’s distribution network, but […]
Cardiology Pharmaceuticals February 2, 2026
CKM’s True Medication Burden February 2, 2026
As cardiology begins to look at the spectrum of cardiovascular-kidney-metabolic disease, new research in JAMA suggests that CKM treatments might face serious adoption challenges due to the sheer number of Americans who both have the disease and qualify for medications. In a search for just how many eligible patients are out there, researchers examined FDA-approved […]
Heart Failure January 29, 2026
Telemedicine’s Unintended HF Consequences January 29, 2026
Heart failure telemedicine doesn’t seem to be lining up evidence-based care after a recent Stanford Medicine analysis revealed that remotely-managed HF patients received less diagnostic testing and saw serious dips in guideline-directed medical therapy. With the rising popularity of remote patient management in cardiology, Stanford researchers decided to explore telemedicine’s HF impact by tracking 44 […]
Heart Failure January 26, 2026
Advancing Heart Failure Care: Timely Referral and Life-prolonging Strategies with HeartMate 3 Left Ventricular Assist Device January 26, 2026
Excerpt from Article by Dr. Sanjeev Gulati, Radcliffe Cardiology 2025; e1. Heart failure (HF) remains a leading cause of morbidity and mortality globally, and advanced HF represents a severe stage of the disease affecting more than 64 million people across the world with rising prevalence.1,2 Most of us are very experienced in the role that […]
Cardiology Policy January 26, 2026
Women Need Lower LV Thresholds for AV Surgery January 26, 2026
New multicenter data published in JAMA suggests that surgery for aortic regurgitation may need to be done earlier than current guidelines recommend, with lower LV size thresholds and possibly different cutoffs for men and women. Studying several cohorts, researchers followed 808 patients with symptomatic AR and preserved LVEF with a median 7-year follow-up examining mortality […]
Cardiac Imaging January 22, 2026
IVUS and OCT Better Than Angiography for PCI January 22, 2026
A recent JACC: Cardiovascular Interventions analysis of 17 randomized trials suggests that intravascular cardiac imaging (intravascular ultrasound or optical coherence tomography) significantly reduces major cardiac events compared with angiography alone when guiding PCI with drug-eluting stents. To help clarify intravascular imaging’s benefits, researchers synthesized data from 17 RCTs of drug-eluting stent PCIs for complex lesions, […]
Cardiology Business January 15, 2026
FTC Wins Lawsuit Against Edwards Over JenaValve January 15, 2026
Following a six-month antitrust fight, Edwards Lifesciences has been forced to walk away from its $945M attempt to buy fledgling valve developer JenaValve after a U.S. district court ruled in favor of the FTC’s decision to block the move. The FTC’s big issue didn’t just start Edwards acquiring JenaValve, rather it was the short timespan […]
Cardiogenetics January 12, 2026
Y Chromosome Loss and MI Risk January 12, 2026
We already know that loss or mutation in genes can lead to increased cardiovascular risk or even cause some diseases, but what about losing a whole chromosome? New research in JACC suggests that men who lose pieces of their Y chromosome as they age could be at greater risk of heart attacks. Researchers measured the […]
Cardiology Testing January 8, 2026
HF Frailty Could Be Simpler than We Think January 8, 2026
A new registry analysis out of Japan suggests we may be able to simplify how we classify heart failure frailty without losing accuracy, allowing us to screen for HF mortality risk in faster and more practical ways. To see how CFS stacks up against comprehensive physical testing, researchers categorized 3.9k patients hospitalized with HF into […]